Figure 3.

OVCAR3 and OVCAR8 cell apoptosis detection by fluorescence-activated cell sorting and cell cycle analysis by flow cytometry. (A) Cell apoptosis was analyzed using Annexin V FITC and (B) quantified. The apoptosis rate in the rhAMH treated group (48 h) was significantly increased compared with the control group (OVCAR3, P=0.035; OVCAR8, P=0.020). The apoptosis rate increased at 72 h but was not significantly different compared with the 48 h group (OVCAR3, P=0.145; OVCAR8, P=0.296). (C) Quantified flow cytometry revealed the number of cells at the G₁ phase. The percentage of cells at G₁ phase in the rhAMH treated group (48 h) increased, but was not significantly different when compared with the control group (OVCAR3, P=0.070; OVCAR8, P=0.051). A significant difference was identified at 72 h compared with the control group (OVCAR3, P=0.016; OVCAR8, P=0.019). (D) Flow cytometry results. *P<0.01 vs. the control. RhAMH, recombinant human anti-Müllerian hormone; FITC, fluorescein isothiocyanate.